SNAC2: A Randomised Trial Of Extending Sentinel Node Based Management To Women With Larger Or Multifocal Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,266,430.00
Summary
SNAC2 extends the work begun in SNAC1, which recruited 1,088 women over 4 years. SNAC1 will determine if sentinel node biopsy causes less arm problems than axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours. SNAC2 is needed to determine whether the smaller operation gives cure rates as good as axillary clearance. If it does, then it will become standard practice.
Preparing Australia For Genomic Medicine: A Proposal By The Australian Genomics Health Alliance
Funder
National Health and Medical Research Council
Funding Amount
$25,000,000.00
Summary
The sequencing of the human genome brings the possibility of more accurate identification of the underlying basis of many diseases. This technology has moved so rapidly, however, that clinical access has been limited. In this application, a national alliance of clinicians, researchers, health economists and policymakers will evaluate the case for clinical genomics across inherited disease and cancer, determine how best to deliver this to the patient and train a capable workforce.
Electrophysiologic Phenotyping Of Non Ischaemic Cardiomyopathy To Predict Clinical Outcome
Funder
National Health and Medical Research Council
Funding Amount
$374,676.00
Summary
Non-ischemic cardiomyopathy (NICM) is a common cause of heart failure and sudden death. Currently, the guidelines for the management are generalised and do not differentiate patients at high risk of disease progression and sudden death. This project aims to identify the electrical and structural properties of heart, to predict the clinical course in patients with NICM. Identification of high-risk patients will help allocate resources wisely and enable appropriate patient counselling.
Blood Protein Biomarkers For Frontotemporal Lobar Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$184,305.00
Summary
This project will assess blood proteins as biomarkers for different pathogenic forms of frontotemporal dementia (FTD), one of the major neurodegenerative dementias with a very rapid disease progression (mean survival 3 years). At present, it is not possible to predict which pathological variant is present in any given patient. We plan to develop blood protein biomarker assays capable of diagnosing the pathology in vivo.
The Mechanism Of Action Of Muscarinic Receptor Antagonists In Preventing Axial Myopia
Funder
National Health and Medical Research Council
Funding Amount
$242,545.00
Summary
Myopia (short-sightedness) is the most common refractive error and is due to the eye being too long and, if uncorrected, results in blurred distance vision. Approximately 30% of the population in developed countries, such as Australia, suffer from myopia. In a significant minority of individuals with high degrees of myopia, it is a sight threatening condition and a leading cause of blindness. It has been found that the pharmacological agent, atropine, is effective in preventing myopia in childre ....Myopia (short-sightedness) is the most common refractive error and is due to the eye being too long and, if uncorrected, results in blurred distance vision. Approximately 30% of the population in developed countries, such as Australia, suffer from myopia. In a significant minority of individuals with high degrees of myopia, it is a sight threatening condition and a leading cause of blindness. It has been found that the pharmacological agent, atropine, is effective in preventing myopia in children and in animal models of myopia. However the side effects of blurred vision at near, glare from dilated pupils and the unknown long term effects of chronic atropine treatment have prevented this approach to myopia control from becoming an established treatment in children. It was originally thought that the drug worked by preventing the eye from accommodating for near objects, however it has now been shown that atropine does not to work by this mechanism, but rather by another non-accommodative mechanism. The aim of this project is to determine the mechanism of action of this class of drugs (known as muscarinic antagonists) in preventing myopic eye growth. The project will investigate in which ocular tissues the various subtypes of muscarinic receptors sensitive to these drugs are located and how these are changed in myopic eyes. It will also determine the specific receptor subtype these drugs act on and whether these drugs inhibit eye growth in myopia by altered retinal signalling activity. The results from this study will elucidate the mechanism and route of action of muscarinic antagonists in preventing myopic eye growth. These findings will advance the probability of developing an effective selective muscarinic antagonist drug to use for the prevention of axial myopia without the side effects associated with the broad-band antagonist atropine. The development of such drugs will have a major economic benefit to the Australian population.Read moreRead less
New High-risk Variants For Colorectal Cancer: The Post-GWAS Era
Funder
National Health and Medical Research Council
Funding Amount
$710,105.00
Summary
Our aim is to discover new genes that greatly increase bowel cancer risk. If we can identify these carriers we may be able to prevent them getting cancer. By studying DNA related to bowel cancer, using a novel family design, we will identify families most likely to carry the new genes. We will focus genetic testing, using new techniques, to look for mutations in these prioritised families. Identified mutations will be tested in a 3,500 bowel cancer cases to see how important they are.